Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
Clinical trial NCT06295211 · COMPLETED
Trial details
- NCT number
- NCT06295211
- Sponsor
- Federico II University
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2013-09-01
- Primary completion
- 2023-09-01
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.